Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

January 27, 2026

Study Completion Date

January 1, 2029

Conditions
Breast Cancer Recurrent
Interventions
DRUG

Palbociclib 125mg

Palbociclib 125 mg oral tablet taken daily for 3 years from randomization

DRUG

Standard endocrine therapy

Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.

Trial Locations (53)

8001

BZ Bethanien, Zurich

14000

Centre Francois Baclesse, Caen

21079

Centre Georges François Leclerc, Dijon

31100

Institut Claudius Regaud, Toulouse

33076

Institut Bergonie, Bordeaux

34298

ICM Val d'Aurelle, Montpellier

49300

Cêntre Hospitaler de Cholet, Cholet

69008

Centre Leon Berard, Lyon

84918

Institut Sainte Catherine, Avignon

87000

Centre Hospitalier Universitaire de Limoges, Limoges

94800

Gustave Roussy, Villejuif

333000

Polyclinique Bordeaux Nord, Bordeaux

Unknown

Medizinische Universität Graz (MUG), Graz

Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde, Innsbruck

Uniklinikum Salzburg, Salzburg

MUW - Universitätsklinik für Innere Medizin, Vienna

Groupe hospitalier de Bretagne Sud, Hôpital du Scorff, Lorient

Centre Paul Strauss, Strasbourg

National Institute of Oncology, Budapest

Cro Irccs, Aviano

ASST Papa Giovanni XXIII, Bergamo

PO Antonio Perrino Brindisi, Brindisi

Istituto scientifico Romagnolo per lo studio e la cura, Meldola

Istituto Europeo di Oncologia, Milan

AOU Maggiore Della Carita, University of Eastern Piedmont, Novara

Azienda Ospedaliero-Universitaria di Parma, Parma

Istituti Clinici Scientifici Maugeri, Pavia

Ospedale S. Stefano, Prato

U.O. Oncologia, Ospedale Infermi, Rimini

Hospital Universitario de Canarias, San Cristóbal de La Laguna

Hospital Universitario de La Coruña, A Coruña

Hospital General Universitario de Alicante, Alicante

Hospital Universitario Vall d´Hebrón, Barcelona

Instituto Catalan de Oncologia L´Hospitalet, Barcelona

Hospital de Basurto, Bilbao

Institut Català d´Oncología (ICO), Girona

Hospital Universitario 12 de Octubre, Madrid

HU Ramón y Cajal, Madrid

Hospital Virgen de la Victoria, Málaga

Hospital Virgen de la Macarena, Seville

Instituto Valenciano de Oncología (IVO), Valencia

Hospital Universitario Río Hortega, Valladolid

Hospital Universitario Miguel Servet, Zaragoza

Kantonsspital Baden, Baden

Brustzentrum Basel Bethesda Spital, Basel

Inselspital Bern, Bern

Centre du Sein Fribourg, Fribourg

Fondazione Oncologia Lago Maggiore, Locarno

Kouros Moccia Oncologia, Locarno

Luzerner Kantonsspital, Lucerne

Kantonsspital Winterthur, Winterthur

Brust-Zentrum AG Zürich, Zurich

06189

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ETOP IBCSG Partners Foundation

NETWORK